Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity

Andrade, Yane; Ropke, Jivago; Viana, Thércia; Fanelli, Chiara; Minaldi, Elisa; Batista, Luara; Issy, Ana; Del Bel, Elaine; Rodrigues, Livia; Liégeois, Jean-François; Moreira, Fabricio

doi:10.1097/FBP.0000000000000595

Request a copy

Article (Scientific journals)

Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity

Andrade, Yane; Ropke, Jivago; Viana, Thércia et al.

2021 • In Behavioural Pharmacology, 32, p. 2-8

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/255919

DOI
10.1097/FBP.0000000000000595

PubMed
33399294

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

BehavPharmacol2021.pdf

Publisher postprint (423.37 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

animal models; antipsychoitcs; dopamine; glutamate; prepulse inhibition; schizophrenia

Research Center/Unit :

CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège

Disciplines :

Animal psychology, ethology & psychobiology
Neurosciences & behavior
Pharmacy, pharmacology & toxicology

Author, co-author :

Andrade, Yane

Ropke, Jivago

Viana, Thércia

Fanelli, Chiara

Minaldi, Elisa

Batista, Luara

Issy, Ana

Del Bel, Elaine

Rodrigues, Livia

Liégeois, Jean-François ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique

Moreira, Fabricio; Universidade Federal de Minas Gerais > Department of Pharmacology > Institute of Biological Sciences

Language :

English

Title :

Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity

Publication date :

2021

Journal title :

Behavioural Pharmacology

ISSN :

0955-8810

eISSN :

1473-5849

Publisher :

Lippincott Williams & Wilkins, United States

Volume :

Pages :

2-8

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 27 January 2021

Statistics

Number of views

109 (9 by ULiège)

Number of downloads

4 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Bruhwyler J, Liégeois J-F, Chleide E, Rogister F, Damas J, Delarge J, Mercier M,. (1992). Comparative study of typical neuroleptics, clozapine and newly synthesized clozapine-analogues: correlations between neurochemistry and behaviour. Behav Pharmacol. 3: 567-579.
Bruhwyler J, Liégeois J-F, Bergman J, Carey G, Goudie A, Taylor A,. (1997). JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties. Pharmacol Res. 36: 255-264.
Carlsson ML, Carlsson A, Nilsson M,. (2004). Schizophrenia: from dopamine to glutamate and back. Curr Med Chem. 11: 267-277.
Casey DE, Bruhwyler J, Delarge J, Géczy J, Liégeois J-F,. (2001). The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates. Psychopharmacology (BERL). 157: 228-235.
da Silveira VT, Röpke J, Matosinhos AL, Issy AC, Del Bel EA, de Oliveira AC, Moreira FA,. (2018). Effects of the monoamine stabilizer (-)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity. Naunyn Schmiedebergs Arch Pharmacol. 391: 761-768.
de Matos LO, de Araujo Lima Reis AL, Lopes Guerra LT, de Oliveira Guarnieri L, Moraes MA, Arabe LB,. (2020). Early postnatal l-Dopa treatment causes behavioral alterations in female vs. male young adult Swiss mice. Neuropharmacology. 170: 108047.
Ellenbroek BA, Liégeois J-F,. (2003). JL 13, an atypical antipsychotic: a preclinical review. CNS Drug Rev. 9: 41-56.
Ellenbroek BA, Liégeois J-F, Bruhwyler J, Cools AR,. (2001). Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. J Pharmacol Exp Ther. 298: 386-391.
Fejgin K, Safonov S, Pålsson E, Wass C, Engel JA, Svensson L, Klamer D,. (2007). The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl). 191: 377-385.
Fendt M, Koch M,. (2013). Translational value of startle modulations. Cell Tissue Res. 354: 287-295.
Gardner DM, Baldessarini RJ, Waraich P,. (2005). Modern antipsychotic drugs: a critical overview. CMAJ. 172: 1703-1711.
Gobira PH, Ropke J, Aguiar DC, Crippa JA, Moreira FA,. (2013). Animal models for predicting the efficacy and side effects of antipsychotic drugs. Braz J Psychiatry. 35 (Suppl 2): S132-S139.
Goff DC, Falkai P, Fleischhacker WW, Girgis RR, Kahn RM, Uchida H,. (2017). The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry. 174: 840-849.
Howes O, McCutcheon R, Stone J,. (2015). Glutamate and dopamine in schizophrenia: an update for the 21stcentury. J Psychopharmacol. 29: 97-115.
Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S,. (2009). Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des. 15: 2550-2559.
Issy AC, Salum C, Del Bel EA,. (2009). Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice. Behav Brain Res. 205: 475-481.
Kapur S,. (2004). How antipsychotics become anti-"psychotic"-from dopamine to salience to psychosis. Trends Pharmacol Sci. 25: 402-406.
Kapur S, Mamo D,. (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 27: 1081-1090.
Kapur S, Mizrahi R, Li M,. (2005). From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res. 79: 59-68.
Laruelle M,. (2014). Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol. 14: 97-102.
Leite JV, Guimaraes FS, Moreira FA,. (2008). Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol. 578: 222-227.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM,. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 373: 31-41.
Liégeois J-F, Bruhwyler J, Hendrick JC, Delarge J, Legros JJ, Damas J,. (2002). Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats. Neurosci Lett. 319: 49-52.
Liégeois J-F, Deville M, Dilly S, Lamy C, Mangin F, Résimont M, Tarazi FI,. (2012). New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation. J Med Chem. 55: 1572-1582.
Liégeois J-F, Mouithys-Mickalad A, Bruhwyler J, Delarge J, Petit C, Kauffmann JM, Lamy M,. (1997). JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena. Biochem Biophys Res Commun. 238: 252-255.
Liégeois J-F, Rogister FA, Bruhwyler J, Damas J, Nguyen TP, Inarejos MO,. (1994). Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study. J Med Chem. 37: 519-525.
McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, CATIE Investigators. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 163: 600-610.
Meltzer HY, Li Z, Kaneda Y, Ichikawa J,. (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 27: 1159-1172.
Meltzer HY, Stahl SM,. (1976). The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 2: 19-76.
Moghaddam B, Javitt D,. (2012). From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 37: 4-15.
Moreira FA, Guimaraes FS,. (2005). Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol. 512: 199-205.
Pedrazzi JF, Issy AC, Gomes FV, Guimarães FS, Del-Bel EA,. (2015). Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology (Berl). 232: 3057-3065.
Snyder SH,. (1972). Catecholamines in the brain as mediators of amphetamine psychosis. Arch Gen Psychiatry. 27: 169-179.
Swerdlow NR, Braff DL, Geyer MA,. (2016). Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol. 30: 1072-1081.
Tarazi FI, Moran-Gates T, Gardner MP, Graulich A, Lamy C, Liégeois J-F,. (2007). Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors. J Mol Neurosci. 32: 192-198.
van Os J, Kapur S,. (2009). Schizophrenia. Lancet. 374: 635-645.
Viana TG, Almeida-Santos AF, Aguiar DC, Moreira FA,. (2013). Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice. Basic Clin Pharmacol Toxicol. 112: 319-324.
Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP,. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 159: 255-262.